Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Novel agents emerge for hemophilia
Shapiro AD, et al. J Thromb Haemost. 2018 Sep 28
Key clinical point: Novel agents under development could replace prothrombin complex concentrates and recombinant factor VIIa in the treatment of hemophilia with inhibitors.
Major finding: The novel targeted agents include emicizumab, a humanized bispecific monoclonal antibody, approved for prophylaxis in hemophilia A; and fitusiran, tissue factor pathway inhibitors, and eptacog beta in development.
Study details: A review article on newer agents that could be used in conjunction with traditional bypassing agents for the treatment of bleeding episodes in patients with hemophilia and high-titer inhibitors.
Disclosures: The review article was supported by an unrestricted educational grant from HEMA Biologics, LLC, which had no involvement or editorial control in research, writing or submission. Dr. Shapiro reported disclosures related to HEMA Biologics, Shire, Novo Nordisk, Kedrion Biopharma, Bioverativ, and Genentech.
Shapiro AD, et al. J Thromb Haemost. 2018 Sep 28.